XSWX
DESN
Market cap5.09bUSD
Jun 18, Last price
296.00CHF
1D
-0.34%
1Q
-10.84%
Jan 2017
588.77%
IPO
1,257.80%
Name
Dottikon Es Holding AG
Chart & Performance
P/E
38.76
P/S
10.62
EPS
7.64
Div Yield, %
—
Shrs. gr., 5y
1.70%
Rev. gr., 5y
17.13%
Revenues
385m
+18.07%
Net income
106m
+30.95%
CFO
96m
-6.82%
Dividend
Jul 09, 20134 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dottikon Es Holding AG operates as a global enterprise, manufacturing and supplying high-performance chemicals, intermediate compounds, and active pharmaceutical ingredients (APIs) to the worldwide chemical, biotechnology, and pharmaceutical sectors. Its extensive product range features a diverse selection of organic compounds, such as various amines, anilines, azaindoles, benzimidazoles, benzoic acid and benzyl derivatives, boron and cyclopropyl building blocks, chiral compounds, cyclohexane derivatives, indazoles, indoles, N- and O-heterocycles, nitrate esters, nitroaromatic compounds, phenols, anisoles, and pyridine building blocks. The company also provides Dottisol, an isosorbide dimethyl ether, which serves as a solubility enhancer in cosmetic, pharmaceutical, and agricultural applications, in addition to being a performance additive across various other industries. Beyond chemical synthesis, Dottikon is engaged in environmental management, offering services like recycling, thermal energy recovery, and high-temperature incineration of waste streams, coupled with advanced wastewater treatment and purification. Furthermore, the firm extends its expertise through consulting services for investment companies, alongside delivering specialized software and engineering solutions. Established in 1913 and based in Dottikon, Switzerland, Dottikon Es Holding AG is a subsidiary of EVOLMA Holding AG.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||